3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
7
Head & Neck
3
Breast
3
Thoracic
2
Sarcoma
2
Gynecologic
2
Gastrointestinal
2
Myeloid
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
379
Lung Neoplasms
246
Small Cell Lung Carcinoma
67
Colorectal Neoplasms
64
Breast Neoplasms
51
Ovarian Neoplasms
44
Melanoma
44
Pancreatic Neoplasms
42
Neoplasms
39
Neoplasm Metastasis
35
Squamous Cell Carcinoma of Head and Neck
33
Stomach Neoplasms
27
Prostatic Neoplasms
27
Head and Neck Neoplasms
26
Esophageal Neoplasms
24
Endometrial Neoplasms
23
Carcinoma, Renal Cell
23
Colonic Neoplasms
22
Urinary Bladder Neoplasms
20
Triple Negative Breast Neoplasms
20
Uterine Cervical Neoplasms
19
Carcinoma, Hepatocellular
19
Sarcoma
13
Mesothelioma, Malignant
13
Mesothelioma
13
Liver Neoplasms
13
Rectal Neoplasms
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Lung Diseases
12
Thyroid Neoplasms
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Thoracic
×
30 days
×
Clear all
NCT06238479
2026-05-22
EXCEED
Eli Lilly and Company
Phase 1
Active not recruiting
490 enrolled
NCT06465069
2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1
Recruiting
420 enrolled